Effects of Fibrates on Metabolism of Statins in Human Hepatocytes

Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

1995 • 601 citations

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.

2001 • 414 citations

Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.

1994 • 390 citations

Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization

2002 • 342 citations

Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins

2002 • 286 citations

In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.

1997 • 274 citations

Statin—Fibrate Combination Therapy

2001 • 273 citations

Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)

1998 • 259 citations

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

2000 • 258 citations

Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.

2000 • 228 citations

In Vitro Analysis of Human Drug Glucuronidation and Prediction of in Vivo Metabolic Clearance

2002 • 221 citations

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

2001 • 192 citations

Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

2001 • 135 citations

Clinical Pharmacokinetics of Cerivastatin

2000 • 118 citations

Learning from the cerivastatin experience

2001 • 108 citations

Metabolic interactions between mibefradil and HMG‐CoA reductase inhibitors: an in vitro investigation with human liver preparations

1999 • 99 citations

Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved.

1997 • 75 citations

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

1999 • 74 citations

Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C

2001 • 63 citations

Inhibitors of fatty acid oxidation

1987 • 60 citations

Biotransformation of cerivastatin in mice, rats, and dogs in vivo.

1998 • 44 citations

Metabolic disposition of simvastatin in patients with T-tube drainage.

1994 • 38 citations

beta-Oxidation of simvastatin in mouse liver preparations.

2001 • 37 citations

The fibrates in clinical practice: Focus on micronised fenofibrate

1994 • 34 citations

Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia

1997 • 17 citations

Effects of gemfibrozil and clofibric acid on the uptake of taurocholate by isolated rat hepatocytes

1997 • 3 citations